In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate

Virology Journal

Volumn 6, Issue , 2009, Pages

  Okeke, Malachy Ifeanyi ^a,b   Nilssen, Ivind ^a,c   Moens, Ugo ^a   Tryland, Morten ^d   Traavik, Terje ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b GenØk Centre for Biosafety   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; POXVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; COWPOX VIRUS; CYTOPLASM VESICLE; GENETIC STABILITY; GOLGI COMPLEX; HA GENE; HOMOLOGOUS RECOMBINATION; HOST RANGE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMAL CELL; MIXED INFECTION; MODIFIED VACCINIA VIRUS ANKARA; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; TRANSGENE; VERO CELL; VIRION; VIROGENESIS; VIRUS HYBRID; VIRUS INFECTION; VIRUS ISOLATION; VIRUS MORPHOGENESIS; VIRUS PLAQUE; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; CELL LINE; CERCOPITHECUS; GENETIC RECOMBINATION; GENETICS; GENOMIC INSTABILITY; ORTHOMYXOVIRUS; PHYSIOLOGY; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALIA; CERCOPITHECUS AETHIOPS; COWPOX VIRUS; MAMMALIA; ORTHOMYXOVIRIDAE; POXVIRIDAE; RATTUS; VACCINIA VIRUS ANKARA;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; COWPOX VIRUS; GENOMIC INSTABILITY; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; RATS; RECOMBINATION, GENETIC; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 66749135772     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-55     Document Type: Article

References (66)

1. Poxviruses as vaccine vectors. PP Pastoret A Vanderplasschen, Comp Immunol Microbiol Infect Dis 2003 26 343 355 10.1016/S0147-9571(03)00019-5 12818621
2. Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. B Brochier MF Aubert PP Pastoret E Masson J Schon M Lombard G Chappuis B Languet P Desmettre, Rev Sci Tech 1996 15 947 970 9025144
3. Early gene expression of vaccinia virus strains replicating (Praha) and non-replicating (modified vaccinia virus strain Ankara, MVA) in mammalian cells. S Nemeckova P Hainz P Otahal P Gabriel V Sroller L Kutinova, Acta Virol 2001 45 243 247 11885931 (Pubitemid 34142901)
4. The uses of poxviruses as vectors. A Vanderplasschen PP Pastoret, Curr Gene Ther 2003 3 583 595 10.2174/1566523034578168 14683453
5. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. RJ Jackson AJ Ramsay CD Christensen S Beaton DF Hall IA Ramshaw, J Virol 2001 75 1205 1210 11152493 10.1128/JVI.75.3.1205-1210.2001
6. Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene. H Hansen MI Okeke O Nilssen T Traavik, Vaccine 2004 23 499 506 10.1016/j.vaccine.2004.06.032 15530698
7. Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. MI Okeke O Nilssen T Traavik, J Gen Virol 2006 87 21 27 10.1099/vir.0.81479-0 16361414
8. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. I Drexler K Heller B Wahren V Erfle G Sutter, J Gen Virol 1998 79 Pt 2 347 352 9472619 (Pubitemid 28048439)
9. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. KJ Stittelaar T Kuiken RL de Swart G van Amerongen HW Vos HG Niesters P van Schalkwijk T van der Kwast LS Wyatt B Moss AD Osterhaus, Vaccine 2001 19 3700 3709 10.1016/S0264-410X(01)00075-5 11395204
10. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. JC Ramirez D Finke M Esteban JP Kraehenbuhl H Acha-Orbea, Arch Virol 2003 148 827 839 10.1007/s00705-003-0006-z 12721793
11. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. T Hanke AJ McMichael MJ Dennis SA Sharpe LA Powell L McLoughlin SJ Crome, Vaccine 2005 23 1507 1514 10.1016/j.vaccine.2004.08.050 15670887
12. Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. CM Corona Gutierrez A Tinoco M Lopez Contreras T Navarro P Calzado L Vargas L Reyes R Posternak R Rosales, Hum Gene Ther 2002 13 1127 1140 10.1089/104303402753812520 12067445
13. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? I Drexler C Staib G Sutter, Curr Opin Biotechnol 2004 15 506 512 10.1016/j.copbio.2004.09.001 15560976
14. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. LS Wyatt PL Earl LA Eller B Moss, Proc Natl Acad Sci USA 2004 101 4590 4595 15070762 10.1073/pnas.0401165101
15. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. CL Smith PR Dunbar F Mirza MJ Palmowski D Shepherd SC Gilbert P Coulie J Schneider E Hoffman R Hawkins, Int J Cancer 2005 113 259 266 10.1002/ijc.20569 15386406
16. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. P Bejon N Peshu SC Gilbert BS Lowe CS Molyneux J Forsdyke T Lang AV Hill K Marsh, Clin Infect Dis 2006 42 1102 1110 10.1086/501459 16575727
17. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. C Samuelsson J Hausmann H Lauterbach M Schmidt S Akira H Wagner P Chaplin M Suter M O'Keeffe H Hochrein, J Clin Invest 2008 118 1776 1784 18398511 10.1172/JCI33940
18. Recombinants between vaccinia and ectromelia viruses bearing the specific pathogenicity markers of both parents. VI Chernos TP Antonova TG Senkevich, J Gen Virol 1985 66 Pt 3 621 626 10.1099/0022-1317-66-3-621 2983005 (Pubitemid 15136815)
19. High-frequency homologous recombination in vaccinia virus DNA. LA Ball, J Virol 1987 61 1788 1795 3573150 (Pubitemid 17080197)
20. Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus. Z Fathi LM Dyster J Seto RC Condit EG Niles, J Gen Virol 1991 72 Pt 11 2733 2737 10.1099/0022-1317-72-11-2733 1940868
21. Tumorigenic poxviruses: genomic organization of malignant rabbit virus, a recombinant between Shope fibroma virus and myxoma virus. W Block C Upton G McFadden, Virology 1985 140 113 124 10.1016/0042-6822(85)90450-7 2981446
22. Poxvirus genetic recombination during natural virus transmission. PD Gershon RP Kitching JM Hammond DN Black, J Gen Virol 1989 70 Pt 2 485 489 10.1099/0022-1317-70-2-485 2543750 (Pubitemid 19051679)
23. Vaccinia virus DNA polymerase promotes DNA pairing and strand-transfer reactions. DO Willer MJ Mann W Zhang DH Evans, Virology 1999 257 511 523 10.1006/viro.1999.9705 10329561
24. Effects of DNA structure and homology length on vaccinia virus recombination. XD Yao DH Evans, J Virol 2001 75 6923 6932 11435572 10.1128/JVI.75.15.6923-6932.2001
25. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. MW Carroll B Moss, Virology 1997 238 198 211 10.1006/viro.1997.8845 9400593
26. Cryo-electron tomography of vaccinia virus. M Cyrklaff C Risco JJ Fernandez MV Jimenez M Esteban W Baumeister JL Carrascosa, Proc Natl Acad Sci USA 2005 102 2772 2777 15699328 10.1073/pnas.0409825102
27. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. JC Gallego-Gomez C Risco D Rodriguez P Cabezas S Guerra JL Carrascosa M Esteban, J Virol 2003 77 10606 10622 12970445 10.1128/JVI.77.19. 10606-10622.2003
28. Structure of intracellular mature vaccinia virus observed by cryoelectron microscopy. J Dubochet M Adrian K Richter J Garces R Wittek, J Virol 1994 68 1935 1941 8107253 (Pubitemid 24065763)
29. Vaccinia virus utilizes microtubules for movement to the cell surface. M Hollinshead G Rodger H Van Eijl M Law R Hollinshead DJ Vaux GL Smith, J Cell Biol 2001 154 389 402 11470826 10.1083/jcb.200104124
30. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Q Fang L Yang W Zhu L Liu H Wang W Yu G Xiao P Tien L Zhang Z Chen, Virology 2005 335 242 251 10.1016/j.virol.2005.02.014 15840523
31. Construction and isolation of recombinant MVA. C Staib I Drexler G Sutter, Methods Mol Biol 2004 269 77 100 15114009
32. Poxvirus genomes: a phylogenetic analysis. C Gubser S Hue P Kellam GL Smith, J Gen Virol 2004 85 105 117 10.1099/vir.0.19565-0 14718625
33. The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. SN Shchelkunov PF Safronov AV Totmenin NA Petrov OI Ryazankina VV Gutorov GJ Kotwal, Virology 1998 243 432 460 10.1006/viro.1998.9039 9568042
34. Poxviruses: past, present and future. EJ Lefkowitz C Wang C Upton, Virus Res 2006 117 105 118 10.1016/j.virusres.2006.01.016 16503070
35. Lack of vaccinia viremia after smallpox vaccination. JF Cummings ME Polhemus C Hawkes M Klote GV Ludwig G Wortmann, Clin Infect Dis 2004 38 456 458 10.1086/381101 14727224
36. Viremia in human Cowpox virus infection. A Nitsche A Kurth G Pauli, J Clin Virol 2007 40 160 162 10.1016/j.jcv.2007.07.014 17765007
37. Human cowpox 196993: a review based on 54 cases. D Baxby M Bennett B Getty, Br J Dermatol 1994 131 598 607 10.1111/j.1365-2133.1994.tb04969.x 7999588
38. Cowpox: a re-evaluation of the risks of human cowpox based on new epidemiological information. D Baxby M Bennett, Arch Virol Suppl 1997 13 1 12 9413521 (Pubitemid 127502126)
39. Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis. A Ramsey-Ewing B Moss, Virology 1995 206 984 993 10.1006/viro.1995.1021 7856109
40. Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. C Upton S Slack AL Hunter A Ehlers RL Roper, J Virol 2003 77 7590 7600 12805459 10.1128/JVI.77.13.7590-7600.2003
41. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. RL Roper EJ Wolffe A Weisberg B Moss, J Virol 1998 72 4192 4204 9557708 (Pubitemid 28188724)
42. The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. EJ Wolffe E Katz A Weisberg B Moss, J Virol 1997 71 3904 3915 9094667 (Pubitemid 27172405)
43. Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. RL Roper LG Payne B Moss, J Virol 1996 70 3753 3762 8648710 (Pubitemid 26157355)
44. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. AA McIntosh GL Smith, J Virol 1996 70 272 281 8523536 (Pubitemid 126508795)
45. Nucleotide sequence of the vaccinia virus hemagglutinin gene. H Shida, Virology 1986 150 451 462 10.1016/0042-6822(86)90309-0 3008418
46. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. M Engelstad ST Howard GL Smith, Virology 1992 188 801 810 10.1016/0042-6822(92)90535-W 1585649
47. Localization and fine structure of a vaccinia virus gene encoding an envelope antigen. P Hirt G Hiller R Wittek, J Virol 1986 58 757 764 3701927 (Pubitemid 16082762)
48. The vaccinia virus A36R protein is a type Ib membrane protein present on intracellular but not extracellular enveloped virus particles. H van Eijl M Hollinshead GL Smith, Virology 2000 271 26 36 10.1006/viro.2000.0260 10814567
49. The vaccinia virus F12L protein is associated with intracellular enveloped virus particles and is required for their egress to the cell surface. H van Eijl M Hollinshead G Rodger WH Zhang GL Smith, J Gen Virol 2002 83 195 207 11752717 (Pubitemid 34030824)
50. The exit of vaccinia virus from infected cells. GL Smith M Law, Virus Res 2004 106 189 197 10.1016/j.virusres.2004.08.015 15567497
51. The formation and function of extracellular enveloped vaccinia virus. GL Smith A Vanderplasschen M Law, J Gen Virol 2002 83 2915 2931 12466468 (Pubitemid 36054337)
52. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. R Blasco JR Sisler B Moss, J Virol 1993 67 3319 3325 8497053 (Pubitemid 23143705)
53. Identification of second-site mutations that enhance release and spread of vaccinia virus. E Katz E Wolffe B Moss, J Virol 2002 76 11637 11644 12388724 10.1128/JVI.76.22.11637-11644.2002
54. Hemadsorption and fusion inhibition activities of hemagglutinin analyzed by vaccinia virus mutants. M Seki M Oie Y Ichihashi H Shida, Virology 1990 175 372 384 10.1016/0042-6822(90)90422-N 2183466
55. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. LS Wyatt IM Belyakov PL Earl JA Berzofsky B Moss, Virology 2008 372 260 272 18048074 10.1016/j.virol.2007.10.033
56. The vaccinia virus 4c and A-type inclusion proteins are specific markers for the intracellular mature virus particle. D Ulaeto D Grosenbach DE Hruby, J Virol 1996 70 3372 3377 8648667 (Pubitemid 26157318)
57. Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells. A Meiser C Sancho J Krijnse Locker, J Virol 2003 77 9931 9942 12941903 10.1128/JVI.77.18. 9931-9942.2003
58. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions. E Katz B Moss, AIDS Res Hum Retroviruses 1997 13 1497 1500 10.1089/aid.1997.13.1497 9390748 (Pubitemid 27500578)
59. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. M Schmelz B Sodeik M Ericsson EJ Wolffe H Shida G Hiller G Griffiths, J Virol 1994 68 130 147 8254722
60. Cholesterol is required for surface transport of influenza virus hemagglutinin. P Keller K Simons, J Cell Biol 1998 140 1357 1367 9508769 10.1083/jcb.140.6.1357
61. An investigation of incorporation of cellular antigens into vaccinia virus particles. O Krauss R Hollinshead M Hollinshead GL Smith, J Gen Virol 2002 83 2347 2359 12237415
62. Characteristics of four cowpox virus isolates from Norway and Sweden. M Tryland T Sandvik H Hansen G Haukenes L Holtet M Bennett R Mehl U Moens O Olsvik T Traavik, Apmis 1998 106 623 635 9725795 (Pubitemid 28369929)
63. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. G Sutter LS Wyatt PL Foley JR Bennink B Moss, Vaccine 1994 12 1032 1040 10.1016/0264-410X(94)90341-7 7975844
64. Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature virus particles into A-type inclusions. TA McKelvey SC Andrews SE Miller CA Ray DJ Pickup, J Virol 2002 76 11216 11225 12388681 10.1128/JVI.76.22.11216-11225.2002
65. Characterization of vaccinia virus intracellular cores: implications for viral uncoating and core structure. K Pedersen EJ Snijder S Schleich N Roos G Griffiths JK Locker, J Virol 2000 74 3525 3536 10729126 10.1128/JVI.74.8.3525- 3536.2000
66. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. GC Carter M Law M Hollinshead GL Smith, J Gen Virol 2005 86 1279 1290 10.1099/vir.0.80831-0 15831938